The primary outcomes of both trials are safety (adverse events) tolerability, and a wide array of
pharmacokinetic outcomes (which are curiously designated as safety issues).
Not exact matches
In general, genetic polymorphisms result in alterations of
pharmacokinetic and / or pharmacodynamics properties which are then reflected in therapy
outcomes that range from potentially life - threatening adverse effects to inadequate therapeutic response.
Pharmacists have specialty training in
pharmacokinetics and pharmacodynamics and have demonstrated improvements in drug utilization and patient
outcomes in outpatient collaborative practice models [6][7].